ECSP077246A - Formulaciones Estabilizadoras - Google Patents
Formulaciones EstabilizadorasInfo
- Publication number
- ECSP077246A ECSP077246A EC2007007246A ECSP077246A ECSP077246A EC SP077246 A ECSP077246 A EC SP077246A EC 2007007246 A EC2007007246 A EC 2007007246A EC SP077246 A ECSP077246 A EC SP077246A EC SP077246 A ECSP077246 A EC SP077246A
- Authority
- EC
- Ecuador
- Prior art keywords
- protein
- storing
- methods
- relatively low
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Se describen formulaciones que son adecuadas para el almacenamiento de proteínas, tal como anticuerpos, sobre un rango relativamente amplio de concentraciones de proteína, pH, y tipos de tampón. También se describen métodos de almacenamiento de una proteína y métodos para identificar una formulación adecuada para el almacenamiento de una proteína específica. En general, una formulación que contiene poco o nada de surfactante, desde nada a concentraciones relativamente bajas de sal, y que requiere una concentración de tampón relativamente baja.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60131104P | 2004-08-13 | 2004-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP077246A true ECSP077246A (es) | 2007-05-30 |
Family
ID=35908214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2007007246A ECSP077246A (es) | 2004-08-13 | 2007-02-13 | Formulaciones Estabilizadoras |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8871201B2 (es) |
| EP (1) | EP1784219B1 (es) |
| JP (1) | JP4948407B2 (es) |
| KR (1) | KR20070092197A (es) |
| CN (1) | CN101022831A (es) |
| AR (1) | AR051009A1 (es) |
| AU (1) | AU2005272603A1 (es) |
| BR (1) | BRPI0514340A (es) |
| CA (1) | CA2575870A1 (es) |
| CR (1) | CR8904A (es) |
| EC (1) | ECSP077246A (es) |
| ES (1) | ES2637854T3 (es) |
| IL (1) | IL181265A0 (es) |
| MX (1) | MX2007001599A (es) |
| NO (1) | NO20070930L (es) |
| RU (1) | RU2007109062A (es) |
| TW (1) | TW200621282A (es) |
| WO (1) | WO2006020935A2 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| SMP200800064B (it) * | 2006-04-21 | 2009-11-06 | Novartis Ag | Composizioni farmaceutiche di anticorpi anti-cd40 antagonista |
| CA2649538C (en) * | 2006-04-21 | 2014-06-03 | Yatin Gokarn | Buffering agents for biopharmaceutical formulations |
| US20080070230A1 (en) * | 2006-06-12 | 2008-03-20 | Wyeth | Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions |
| EP1950225A1 (de) * | 2007-01-25 | 2008-07-30 | Octapharma AG | Verfahren zur Steigerung von Proteinausbeuten |
| CA2681752A1 (en) | 2007-03-29 | 2008-10-09 | Abbott Laboratories | Crystalline anti-human 1l-12 antibodies |
| US8420081B2 (en) * | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| MX2011005672A (es) * | 2008-11-28 | 2011-06-20 | Abbott Lab | Composiciones de anticuerpo estables y metodos para estabilizar a las mismas. |
| EP2403873A1 (en) | 2009-03-05 | 2012-01-11 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| US20100278822A1 (en) * | 2009-05-04 | 2010-11-04 | Abbott Biotechnology, Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| EP2473528B1 (en) | 2009-09-03 | 2014-12-03 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| EA026226B1 (ru) * | 2011-07-01 | 2017-03-31 | Байоджен Айдек Ма Инк. | Не содержащие аргинина композиции слитого fc-полипептида и способы их применения |
| AU2012345777B2 (en) | 2011-11-30 | 2016-05-12 | Kindeva Drug Delivery L.P. | Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same |
| JP6265970B2 (ja) * | 2012-03-26 | 2018-01-24 | サノフイ | 安定なIgG4に基づく結合剤の製剤 |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US9844594B2 (en) * | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| RU2016119491A (ru) | 2013-11-04 | 2017-12-11 | Пфайзер Инк. | Конъюгаты антитела к efna4 с лекарственным средством |
| ES2939940T3 (es) | 2014-03-28 | 2023-04-28 | Univ Duke | Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| AU2015292822B2 (en) * | 2014-07-21 | 2021-11-25 | Unchained Labs | Determination of protein aggregation from the concentration dependence of delta G |
| MX384605B (es) | 2015-04-29 | 2025-03-14 | Radius Pharmaceuticals Inc | Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno. |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| EA201990316A1 (ru) | 2016-08-18 | 2019-07-31 | Ридженерон Фармасьютикалз, Инк. | Анализ для определения потенциала самоассоциации белка с использованием концентрационно-зависимой спектроскопии самовзаимодействия на основе наночастиц |
| ES3064802T3 (en) | 2016-10-21 | 2026-04-29 | Amgen Inc | Pharmaceutical formulations and methods of making the same |
| EP3565542B1 (en) | 2017-01-05 | 2024-04-10 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
| SG11202013177WA (en) | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals Inc | Polymorphic forms of rad 1901-2hcl |
| US12441745B2 (en) | 2019-02-12 | 2025-10-14 | Radius Pharmaceuticals, Inc. | Processes and compounds |
| AU2021262609A1 (en) * | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| WO2022154529A1 (ko) * | 2021-01-14 | 2022-07-21 | 한올바이오파마주식회사 | 안정화제를 사용하지 않고도 안정한, 탄파너셉트를 포함하는 안과용 조성물 |
| CN115541895B (zh) * | 2022-11-29 | 2023-05-19 | 天津德祥生物技术股份有限公司 | 一种提高微流控反定检测卡灵敏度的配方液及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3176517D1 (en) | 1980-04-24 | 1987-12-17 | Beecham Group Plc | Beta-lactam compounds, their preparation and use |
| GB8518416D0 (en) | 1985-07-22 | 1985-08-29 | Beecham Group Plc | Compounds |
| US5869053A (en) * | 1988-03-04 | 1999-02-09 | Cancer Research Campaign Technology, Ltd. | 5T4 antigen from human trophoblasts |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| PT1012259E (pt) | 1997-06-04 | 2009-11-06 | Oxford Biomedica Ltd | Vector dirigido a tumor |
| ATE230277T1 (de) * | 1997-06-13 | 2003-01-15 | Genentech Inc | Stabilisierte antikörperformulierung |
| AU2444899A (en) | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| JP4516711B2 (ja) * | 1999-12-28 | 2010-08-04 | 中外製薬株式会社 | 安定な抗体組成物及び注射製剤 |
| US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
| DE60139944D1 (de) * | 2000-10-12 | 2009-10-29 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| NZ533657A (en) * | 2002-01-03 | 2008-01-31 | Smithkline Beecham Corp | Methods for the preparation of immunoconjugates, in particular maytansinoids conjugated to a monoclonal antibody |
| BR122019027966B8 (pt) | 2002-05-02 | 2021-07-27 | Wyeth Corp | conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos |
| AU2003251592A1 (en) * | 2002-06-21 | 2004-01-06 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| JP2007528868A (ja) * | 2003-08-14 | 2007-10-18 | ワイス | 抗ルイスy抗イディオタイプ抗体およびその使用 |
| CA2578131A1 (en) | 2004-09-10 | 2006-03-23 | Wyeth | Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates |
-
2005
- 2005-08-11 TW TW094127308A patent/TW200621282A/zh unknown
- 2005-08-12 CN CNA2005800274833A patent/CN101022831A/zh active Pending
- 2005-08-12 RU RU2007109062/13A patent/RU2007109062A/ru not_active Application Discontinuation
- 2005-08-12 KR KR1020077003502A patent/KR20070092197A/ko not_active Withdrawn
- 2005-08-12 ES ES05803522.1T patent/ES2637854T3/es not_active Expired - Lifetime
- 2005-08-12 WO PCT/US2005/028861 patent/WO2006020935A2/en not_active Ceased
- 2005-08-12 CA CA002575870A patent/CA2575870A1/en not_active Abandoned
- 2005-08-12 US US11/203,367 patent/US8871201B2/en active Active
- 2005-08-12 AU AU2005272603A patent/AU2005272603A1/en not_active Abandoned
- 2005-08-12 MX MX2007001599A patent/MX2007001599A/es unknown
- 2005-08-12 JP JP2007525855A patent/JP4948407B2/ja not_active Expired - Fee Related
- 2005-08-12 BR BRPI0514340-3A patent/BRPI0514340A/pt not_active IP Right Cessation
- 2005-08-12 EP EP05803522.1A patent/EP1784219B1/en not_active Expired - Lifetime
- 2005-08-16 AR ARP050103456A patent/AR051009A1/es unknown
-
2007
- 2007-02-06 CR CR8904A patent/CR8904A/es not_active Application Discontinuation
- 2007-02-11 IL IL181265A patent/IL181265A0/en unknown
- 2007-02-13 EC EC2007007246A patent/ECSP077246A/es unknown
- 2007-02-19 NO NO20070930A patent/NO20070930L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1784219A2 (en) | 2007-05-16 |
| IL181265A0 (en) | 2007-07-04 |
| JP2008515775A (ja) | 2008-05-15 |
| US20060115472A1 (en) | 2006-06-01 |
| TW200621282A (en) | 2006-07-01 |
| WO2006020935A2 (en) | 2006-02-23 |
| MX2007001599A (es) | 2007-04-10 |
| US8871201B2 (en) | 2014-10-28 |
| BRPI0514340A (pt) | 2008-06-10 |
| CN101022831A (zh) | 2007-08-22 |
| NO20070930L (no) | 2007-05-14 |
| KR20070092197A (ko) | 2007-09-12 |
| CR8904A (es) | 2007-08-28 |
| RU2007109062A (ru) | 2008-09-20 |
| CA2575870A1 (en) | 2006-02-23 |
| EP1784219A4 (en) | 2010-02-17 |
| EP1784219B1 (en) | 2017-05-17 |
| JP4948407B2 (ja) | 2012-06-06 |
| ES2637854T3 (es) | 2017-10-17 |
| WO2006020935A3 (en) | 2007-03-08 |
| AR051009A1 (es) | 2006-12-13 |
| AU2005272603A1 (en) | 2006-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR8904A (es) | Formulaciones estabilizadoras | |
| CY1121461T1 (el) | Συνθεσεις που περιλαμβανουν δυσδιαλυτους στο νερο φαρμακευτικους παραγοντες και αντιμικροβιακους παραγοντες | |
| CL2017002488A1 (es) | Formulación farmacéutica estable para administración intratecal que comprende una proteína arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que además puede contener un agente estabilizante; contenedor que comprende dicha formulación; uso para tratar la enfermedad leucodistrofia metacrómatica (mld). (divisional solicitud 3654-2012) | |
| ES2535084T3 (es) | Proteínas N-glicosiladas recombinantes procedentes de células procariotas | |
| TR201905081T4 (tr) | Protein içeren formülasyonların stabilizasyonu için yararlı bileşimler ve yöntemler. | |
| AR059964A1 (es) | Metodos para reducir la aglomeracion de proteina | |
| MX2010008416A (es) | Composiciones antimicrobianas y metodos de uso de las mismas. | |
| CO6382079A2 (es) | Composiciones insecticidas estables a base de sulfoximina | |
| AR047949A1 (es) | Preparacion farmaceutica que comprende un anticuerpo contra el receptor de factor de crecimiento endotelial | |
| ECSP088109A (es) | Composición agrícola | |
| MX2009006594A (es) | Formulaciones de ph regulado y estables que contienen polipeptidos. | |
| PE20120342A1 (es) | Formulacion de anticuerpo | |
| JP2017222654A5 (es) | ||
| PE20070796A1 (es) | Metodo de produccion proteica utilizando compuestos anti-senescencia | |
| AR055708A1 (es) | Composicion de acaros, uso de la misma, metodo para criar un acaro predatorio phytoseiid, sistema de crianza para criar dicho acaro predatorio phytoseiid y metodos para el control biologico de pestes en un cultivo | |
| AR083034A1 (es) | ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO | |
| CO6640258A2 (es) | Formulaciones de anticuerpos de alta concentración | |
| BR112015022210A8 (pt) | formulações de anticorpo | |
| PE20070723A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| CL2011000255A1 (es) | Composicion liquida que comprende una proteina o polipeptido harpin, un portador acuoso, un agente biocida y opcionalmente un inhibidor de proteasa y surfactante no ionico; metodo para preparar dicha composicion; y metodo para inducir respuesta en una planta por aplicacion de dicha composicion. | |
| BR102014025328B8 (pt) | Composição herbicida aquosa estável, e método para controle de vegetação indesejável | |
| ATE508190T1 (de) | Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien | |
| MX375672B (es) | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9. | |
| MY157394A (en) | Ultra-high loading glyphosate concentrate | |
| UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa |